NASDAQ:AKYA Akoya Biosciences (AKYA) Stock Price, News & Analysis $1.29 0.00 (0.00%) As of 07/8/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Akoya Biosciences Stock (NASDAQ:AKYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akoya Biosciences alerts:Sign Up Key Stats Today's Range$1.29▼$1.2950-Day Range$1.12▼$1.3752-Week Range$0.93▼$3.42VolumeN/AAverage Volume416,191 shsMarket Capitalization$64.44 millionP/E RatioN/ADividend YieldN/APrice Target$2.51Consensus RatingHold Company Overview Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Read More Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKYA Stock News HeadlinesBrokerages Set Akoya Biosciences, Inc. (NASDAQ:AKYA) Price Target at $2.51July 21, 2025 | americanbankingnews.comAKYA Akoya Biosciences, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAJune 20, 2025 | prnewswire.comKent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative ProposalMay 23, 2025 | prnewswire.comAkoya surges as unsolicited buyout offer risks Quanterix mergerMay 21, 2025 | msn.comAkoya Biosciences Reports First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAMay 7, 2025 | businesswire.comSee More Headlines AKYA Stock Analysis - Frequently Asked Questions How have AKYA shares performed this year? Akoya Biosciences' stock was trading at $2.29 at the beginning of the year. Since then, AKYA shares have decreased by 43.7% and is now trading at $1.29. How were Akoya Biosciences' earnings last quarter? Akoya Biosciences, Inc. (NASDAQ:AKYA) released its quarterly earnings results on Monday, May, 12th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.03. The firm earned $16.64 million during the quarter, compared to the consensus estimate of $20.19 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 487.85% and a negative net margin of 59.44%. When did Akoya Biosciences IPO? Akoya Biosciences (AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO. Who are Akoya Biosciences' major shareholders? Top institutional shareholders of Akoya Biosciences include Vanguard Personalized Indexing Management LLC (0.06%). Insiders that own company stock include Matthew Winkler, Garry PhD Nolan, Brian Mckelligon, John Frederick Ek, Frederic Pla and Joseph Driscoll. View institutional ownership trends. How do I buy shares of Akoya Biosciences? Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akoya Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akoya Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/12/2025Today7/31/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AKYA CIK1711933 Webwww.akoyabio.com Phone855-896-8401FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Akoya Biosciences$2.51 High Price Target$5.00 Low Price Target$1.08 Potential Upside/Downside+94.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.37 million Net Margins-59.44% Pretax Margin-59.28% Return on Equity-487.85% Return on Assets-35.86% Debt Debt-to-Equity Ratio10.12 Current Ratio0.61 Quick Ratio0.40 Sales & Book Value Annual Sales$79.96 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book8.60Miscellaneous Outstanding Shares49,954,000Free Float46,307,000Market Cap$64.44 million OptionableOptionable Beta1.36 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AKYA) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.